Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?

International journal of cancer - 1 Jan 2017

Synnott N C, Murray A, McGowan P M, Kiely M, Kiely P A, O'Donovan N, O'Connor D P, Gallagher W M, Crown J, Duffy M J

Abstract excerpt

The identification and validation of a targeted therapy for patients with triple-negative breast cancer (TNBC) is currently one of the most urgent needs in breast cancer therapeutics. One of the key reasons for the failure to develop a new therapy for this subgroup of breast cancer patients has been the difficulty in identifying a highly prevalent, targetable molecular alteration in these tumors. Recently...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aza Compounds
Share to Bridged Bicyclo Compounds, Heterocyclic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Movement

Share to Cell Survival

Share to Gene Expression Regulation, Neoplastic

Share to Molecular Targeted Therapy

Share to Triple Negative Breast Neoplasms

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 27615392
DOI: 10.1002/ijc.30425

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?PMID 27615392Read ↗

Mutant p53 in breast cancer: potential as a therapeutic target and biomarker.Semantic proximity Read ↗

PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein.Semantic proximity Read ↗

PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial TherapiesSemantic proximity Read ↗

p53 as a target for the treatment of cancer.Semantic proximity Read ↗

Role of p53 Gene in Breast Cancer: Focus on Mutation Spectrum and Therapeutic StrategiesSemantic proximity Read ↗

PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis.Semantic proximity Read ↗

PRIMA-1 synergizes olaparib-induced cell death in p53 mutant triple negative human breast cancer cell line via restoring p53 function, arresting cell cycle, and inducing apoptosisSemantic proximity Read ↗

PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53.Semantic proximity Read ↗

Mutant p53 as a target for cancer treatment.Semantic proximity Read ↗

p53 reactivating small molecule PRIMA‑1MET/APR‑246 regulates genomic instability in MDA‑MB‑231 cells.Semantic proximity Read ↗

Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?Semantic proximity Read ↗

p53, BRCA1 and breast Cancer chemoresistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.